These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 30551641)

  • 1. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
    Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
    Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
    Kazerooni R; Broadhead C
    Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.
    Marciniak C; McAllister P; Walker H; Brashear A; Edgley S; Deltombe T; Khatkova S; Banach M; Gul F; Vilain C; Picaut P; Grandoulier AS; Gracies JM;
    PM R; 2017 Dec; 9(12):1181-1190. PubMed ID: 28625615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost analysis of the use of botulinum toxin type A in Spain].
    de Andrés-Nogales F; Morell A; Aracil J; Torres C; Oyagüez I; Casado MA
    Farm Hosp; 2014 May; 38(3):193-201. PubMed ID: 24951903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.
    Byun J; Kwak S; Kwon JH; Shin M; Lee DK; Rhee CH; Kang WH; Oh JW; Cruz DJM
    Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.
    Rupp D; Nicholson G; Canty D; Wang J; Rhéaume C; Le L; Steward LE; Washburn M; Jacky BP; Broide RS; Philipp-Dormston WG; Brin MF; Brideau-Andersen A
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32545832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.
    Park J; Lee MS; Harrison AR
    Clin Ophthalmol; 2011; 5():725-32. PubMed ID: 21691580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence on botulinum toxin in selected disorders.
    Zakin E; Simpson D
    Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum Toxins Type A (Bont-A) in the Management of Lower Limb Spasticity in Children: A Systematic Literature Review and Bayesian Network Meta-analysis.
    Guyot P; Kalyvas C; Mamane C; Danchenko N
    J Child Neurol; 2019 Jun; 34(7):371-381. PubMed ID: 30803305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of botulinum neurotoxin type A formulations in Asia.
    Frevert J; Ahn KY; Park MY; Sunga O
    Clin Cosmet Investig Dermatol; 2018; 11():327-331. PubMed ID: 30013379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.
    Ravenni R; De Grandis D; Mazza A
    Neurol Sci; 2013 Jul; 34(7):1043-8. PubMed ID: 23576131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
    Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
    Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.
    Brown M; Nicholson G; Ardila MC; Satorius A; Broide RS; Clarke K; Hunt T; Francis J
    J Neural Transm (Vienna); 2013 Feb; 120(2):291-8. PubMed ID: 22842675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.